Close

Nonpartisan Budget Experts Warn Speaker Pelosi’s Drug Pricing Bill will Stifle the Development of New Medicines

BIO’s President and CEO Jim Greenwood issued the following statement after the Congressional Budget Office released an analysis confirming that H.R. 3 will lead to fewer new medicines for patients.

Biotechnology Innovation Organization Announces 2021 Leadership Transition

The Biotechnology Innovation Organization (BIO) today announced that industry veteran Jim Greenwood will step down as President and CEO of the world’s largest biotechnology organization after the 2020 election and help transition a new leader to represent the industry globally and to defend innovation from domestic political attacks.

RFS Proposal Supports Green Energy Breakthroughs

The Biotechnology Innovation Organization (BIO) today released the following statement on the administration’s proposal on the Renewable Fuel Standard. The following statement may be attributed to Stephanie Batchelor, vice president of BIO's industrial & environmental section:

Pediatrics: BIO Comments on FDA Draft Guidance on Rare Pediatric Priority Review Vouchers

September 30, 2019

...

ICH: BIO Comments on ICH E8(R1) General Considerations for Clinical Studies

September 30, 2019

...

ICH: BIO Comments on FDA Draft Guidance ICH E19 Optimisation of Safety Data Collection

September 25, 2019

...

ICH: BIO Submits Comments on FDA Draft Guidance ICH M10 Bioanalytical Method Validation

September 25, 2019

...

New Executive Order Critical to Protecting Patients and Public Health

President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination. 

Speaker Pelosi’s Drug Pricing Plan “Crushes the Desperate Hopes of Patients and their Families”

Washington, D.C. (September 19, 2019) – Former Congressman Jim Greenwood, the President and CEO of the Biotechnology Innovation Organization (BIO), issued the following...

BIO Submits Comments on FDA : New Drug Regulatory Program Modernization: Improving Approval Package Documentation and Communication

The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments regarding the New Drug Regulatory Modernization: Improving Approval Package Documentation and Communication.